| Biomarker ID | 746 |
| PMID | 19934327 |
| Year | 2009 |
| Biomarker | Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.79 (0.62–0.99) |
| Effect on Pathways | Pathways Include:-RORA activates circadian expression,BMAL1-CLOCK/NPAS2 activates circadian expression,Circadian rhythm,Lipid metabolism regulation by peroxisome proliferator-activated receptor alpha (PPAR-alpha),Fatty acid, triacylglycerol, and ketone body metabolism |
| Experiment | Controls Vs More Agressive Disease |
| Type of Biomarker | Diagnostic |
| Cohort | Total of 1308 patients with Prostate cancer and 1266 patients as controls were used for this study. Out of which 873 were less agressive and 435 were more aggressive. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | PCR |
| Clinical | No |
| Remarks | Circadian-related genes were chosen for this study |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NPAS2 |